1
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Lomas RJ, Chandrasekar A, Macdonald-Wallis C, Kaye S, Rauz S, Figueiredo FC. Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK. Eye (Lond) 2021; 35:3425-3432. [PMID: 34531551 PMCID: PMC8602237 DOI: 10.1038/s41433-021-01560-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 02/03/2021] [Accepted: 04/13/2021] [Indexed: 11/09/2022] Open
Abstract
INTRODUCTION Serum eye drops (SED) are an important treatment for patients with chronic and severe ocular surface disease (OSD). Despite a long history of use, there is a paucity of information on patient-reported outcomes, particularly comparing autologous SED (Auto-SED) and allogeneic SED (Allo-SED). National Health Service Blood and Transplant is the national provider of SED service for patients in the UK. PURPOSE To evaluate and compare patient-reported outcome measures (PROMs) in patients receiving Auto-SED and Allo-SED for severe OSD. MATERIALS AND METHODS PROMs were retrospectively collected from all new patients commencing treatment with Auto-SED and Allo-SED between January 2017 and September 2018, using the Ocular Surface Disease Index (OSDI) 12-item questionnaire. A linear mixed model was used to evaluate the change in OSDI scores between baseline and follow-up. RESULTS During the study period, 279 patients who received either Auto-SED (n = 71) or Allo-SED (n = 208) were included in the analysis. Baseline and follow-up OSDI scores were available for 161 of these (49 Auto-SED and 112 Allo-SED). There was a significant reduction in mean OSDI score for both Auto-SED (59.06-24.63, p < 0.001) and Allo-SED (64.21-34.37, p < 0.001). There was no significant difference between Auto-SED and Allo-SED patients in terms of the reduction in the OSDI score (p = 0.27). CONCLUSION Both Auto-SED and Allo-SED were associated with improvements in the quality of life of patients with chronic and severe OSD. Auto-SED and Allo-SED were equally effective in relieving the symptoms of OSD.
Collapse
Affiliation(s)
- R J Lomas
- NHS Blood & Transplant Tissue and Eye Services, Liverpool Centre, Liverpool, UK.
| | - A Chandrasekar
- NHS Blood & Transplant Tissue and Eye Services, Liverpool Centre, Liverpool, UK
| | | | - S Kaye
- The Royal Liverpool University Hospital, Liverpool, UK
| | - S Rauz
- University of Birmingham (UK) and Birmingham & Midland Eye Centre, Birmingham, UK
| | - F C Figueiredo
- Department of Ophthalmology, Royal Victoria Infirmary and Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
3
|
Scaranti M, Caldwell R, Miralles MS, Shinde R, Pal A, Ang J, Biondo A, Guo C, Cojocaru E, Gennatas S, Lockie F, Bertan C, Baker C, Carreira S, Banerjee S, Kaye S, de Bono J, Banerji U, Minchom A, Lopez J. Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Graham C, Liu P, Kaye S. INTEGRATION OF MEDICARE AND MEDICAID: RESULTS OF CALIFORNIA’S DUAL FINANCIAL ALIGNMENT DEMONSTRATION. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- C Graham
- University of California, San Francisco
| | - P Liu
- University of California, San Francisco
| | - S Kaye
- Community Living Policy Center, UCSF
| |
Collapse
|
5
|
Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol 2018; 29:766-771. [PMID: 29351570 PMCID: PMC5889024 DOI: 10.1093/annonc/mdy002] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- N Gaspar
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France.
| | - L V Marshall
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - D Binner
- Create for Chloe and UK Representative for aPODD, European Medicines Agency, London, UK
| | - R Herold
- Product Development Scientific Support Department, European Medicines Agency, London, UK
| | - R Rousseau
- Gritstone Oncology, Inc., Emeryville, USA
| | - P Blanc
- Imagine for Margo, Fourqueux, France
| | | | - J Carleer
- Belgium Federal Agency for Medicines and Health Products, EUROSTATION, Brussels, Belgium
| | - C Copland
- Centre for English Language Teaching, University of York, York, UK
| | - Y Kerloeguen
- Pharmaceuticals Division, PDOA, Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - K Norga
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK; Universitair Ziekenhuis Antwerpen, Edegem, Belgium
| | | | | | - C Spadoni
- aPODD Foundation, City Point, London, UK
| | - J Sterba
- Pediatric Oncology Department, University Hospital Brno, School of Medicine Masaryk University Brno, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, St. Anna University Hospital Brno, Czech Republic
| | - F Ligas
- Product Development Scientific Support Department, European Medicines Agency, London, UK
| | - T Taube
- Boehringer Ingelheim, Pharma GmbH&Co KG, TA Oncology, Biberach, Germany
| | | | - S Chioato
- Regulatory Strategy Oncology, Pfizer Italia, Milano, Italy
| | - M A O'Connell
- Regulatory Strategy Oncology, Pfizer Italia, Milano, Italy
| | - B Geoerger
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France
| | - J-Y Blay
- Centre Léon Bérard and University Claude Bernard Lyon 1, Lyon
| | - J C Soria
- Drug Development Department (DITEP), Gustave Roussy, Villejuif and University Paris-Sud, Orsay, France
| | - S Kaye
- Adult Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK
| | - B Wulff
- Paediatric Haematology/Oncology, Clinical Research/Paediatric Drug Development, University Childreńs Hospital III Hufelandstraße, Essen, Germany
| | - L Brugières
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France
| | - G Vassal
- Department of Clinical Research, Gustave Roussy, Villejuif and Paris-Sud University, Le Kremlin-Bicêtre, France
| | - A D J Pearson
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| |
Collapse
|
6
|
Grierson BA, Yuan X, Gorelenkova M, Kaye S, Logan NC, Meneghini O, Haskey SR, Buchanan J, Fitzgerald M, Smith SP, Cui L, Budny RV, Poli FM. Orchestrating TRANSP Simulations for Interpretative and Predictive Tokamak Modeling with OMFIT. Fusion Science and Technology 2018. [DOI: 10.1080/15361055.2017.1398585] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- B. A. Grierson
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - X. Yuan
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - M. Gorelenkova
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - S. Kaye
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - N. C. Logan
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | | | - S. R. Haskey
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - J. Buchanan
- CCFE, Culham Science Centre, Abingdon, OX14 3DB, United Kingdom
| | - M. Fitzgerald
- CCFE, Culham Science Centre, Abingdon, OX14 3DB, United Kingdom
| | - S. P. Smith
- General Atomics, San Diego, California 92121
| | - L. Cui
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - R. V. Budny
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - F. M. Poli
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| |
Collapse
|
7
|
Kernt K, Martinez M, Bertin D, Stroman D, Cupp G, Martinez C, Tirado M, Guasch J, Kernt K, Lizin F, Cano J, Wesner M, Alemany P, Jungmann P, Partouche P, Sitruk A, Christmann T, Kandarakis A, Royo M, Arias A, Bacquaert J, Dua H, Tomazzoli L, Forsman E, Gerstenberger A, Bertel F, Bouzas E, Trimarchi F, Kaye S, Orsoni G, Klauss V, Mandel S, Mortemousque B. A Clinical Comparison of Two Formulations of Tobramycin 0.3% Eyedrops in the Treatment of Acute Bacterial Conjunctivitis. Eur J Ophthalmol 2018. [DOI: 10.1177/112067210501500504] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To compare the safety and efficacy of a new enhanced viscosity ophthalmic formulation of tobramycin, given twice daily (BID), with the existing four times daily (QID) treatment regimen in patients with acute bacterial conjunctivitis. Methods This was a 12-day, multicenter, observer-masked, randomized, parallel group study. Patients received one drop of tobramycin 0.3% (3 mg/mL) enhanced viscosity ophthalmic solution BID or tobramycin 0.3% (3 mg/mL) ophthalmic solution QID in the affected eyes for 7 days. The primary efficacy variable was the percentage of patients with sustained cure/presumed bacterial eradication based on clinical judgment at the test-of-cure visit (Day 12). Pretherapy bacterial isolates were obtained and tested for susceptibility to tobramycin by determination of minimum inhibitory concentrations (MIC). Results A total of 276 patients were enrolled in the study and 203 of these were culture positive and attended all follow-up examinations. In this group, 98% of those treated with tobramycin enhanced viscosity ophthalmic solution and 99% of those treated with tobramycin 0.3% ophthalmic solution were categorized as having sustained cure/presumed eradication at the test-of-cure visit (p=0.6037). Reported adverse events were not serious, mild to moderate in severity, and generally did not prevent continuation in the study. Several pretreatment pathogens demonstrated tobramycin resistance (MIC > 4 mg/mL). However, therapy with both treatments was effective in the majority of the cases. Conclusions Tobramycin enhanced viscosity ophthalmic solution is well tolerated and has equivalent efficacy to the established treatment regimen with a simplified posology. The formulation provides an alternative therapy for acute bacterial conjunctivitis that should improve patient compliance and satisfaction.
Collapse
Affiliation(s)
- K. Kernt
- Augenärztpraxis, Muenchen, Germany
| | - M. Martinez
- R&D Clinical Sciences AlconCusí, Barcelona - Spain
| | - D. Bertin
- R&D Clinical Sciences, Milano - Italy
| | - D. Stroman
- R&D Microbiology, Alcon Research, Ltd., Fort Worth, Texas - USA
| | - G. Cupp
- R&D Microbiology, Alcon Research, Ltd., Fort Worth, Texas - USA
| | - C. Martinez
- R&D Clinical Sciences AlconCusí, Barcelona - Spain
| | - M. Tirado
- R&D Clinical Sciences AlconCusí, Barcelona - Spain
| | - J. Guasch
- R&D Clinical Sciences AlconCusí, Barcelona - Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - H. Dua
- Nottingham, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ingles Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Sundar R, Kaye S, de Bono J, Banerji U, Lopez J. Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Murakami M, Arunasalam V, Bell J, Bell M, Bitter M, Blanchard W, Boody F, Boyd D, Bretz N, Bush C, Callen J, Cecchi J, Colchin R, Coonrod J, Davis S, Dimock D, Dylla H, Efthimion P, Emerson L, England A, Eubank H, Fonck R, Fredrickson E, Furth H, Grisham L, von Goeler S, Goldston R, Grek B, Grove D, Hawryluk R, Hendel H, Hill K, Hulse R, Johnson D, Johnson L, Kaita R, Kamperschroer J, Kaye S, Kikuchi M, Kilpatrick S, Kugel H, LaMarche P, Little R, Ma C, Manos D, Mansfield D, McCarthy M, McCann R, McCune D, McGuire K, Meade D, Medley S, Mikkelsen D, Mueller D, Nieschmidt E, Owens D, Pare V, Park H, Prichard B, Ramsey A, Rasmussen D, Roquemore A, Rutherford P, Sauthoff N, Schivell J, Schwob JL, Scott S, Sesnic S, Shimada M, Simpkins J, Sinnis J, Stauffer F, Stratton B, Suckewer S, Tait G, Taylor G, Tenney F, Thomas C, Towner H, Ulrickson M, Wieland R, Williams M, Wong KL, Wouters A, Yamada H, Yoshikawa S, Young K, Zarnstorff M. Confinement Studies In TFTR. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst85-a40115] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Murakami
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - V. Arunasalam
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J.D. Bell
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - M.G. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Bitter
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - W.R. Blanchard
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Boody
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Boyd
- Permanent Address: University of Maryland, College Park, MD
| | - N. Bretz
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.E. Bush
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J.D. Callen
- Permanent Address: University of Wisconsin, Madison, WI
| | - J.L. Cecchi
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Colchin
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J. Coonrod
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.L. Davis
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Dimock
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H.F. Dylla
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.C. Efthimion
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.C. Emerson
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - A.C. England
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H.P. Eubank
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Fonck
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - E. Fredrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H.P. Furth
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.R. Grisham
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. von Goeler
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Goldston
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - B. Grek
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.J. Grove
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Hawryluk
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Hendel
- Permanent Address: RCA David Sarnoff Research Center, Princeton, NJ
| | - K.W. Hill
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Hulse
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.C. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Kaita
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J. Kamperschroer
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.M. Kaye
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Kikuchi
- Permanent Address: Japan Atomic Energy Research Institute, Japan
| | - S. Kilpatrick
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Kugel
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.H. LaMarche
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Little
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.H. Ma
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - D. Manos
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Mansfield
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. McCarthy
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.T. McCann
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.C. McCune
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K. McGuire
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.M. Meade
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.S. Medley
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.R. Mikkelsen
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Mueller
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | | | - D.K. Owens
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - V.K. Pare
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - B. Prichard
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - A. Ramsey
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.A. Rasmussen
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - A.L. Roquemore
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.H. Rutherford
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - N.R. Sauthoff
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J. Schivell
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J-L. Schwob
- Permanent Address: Hebrew University of Jerusalem, Israel
| | - S.D Scott
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. Sesnic
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Shimada
- Permanent Address: Japan Atomic Energy Research Institute, Japan
| | - J.E. Simpkins
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J. Sinnis
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Stauffer
- Permanent Address: University of Maryland, College Park, MD
| | - B. Stratton
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. Suckewer
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - G.D. Tait
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - G. Taylor
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Tenney
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.E. Thomas
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H.H. Towner
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Ulrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Wieland
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Williams
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K-L. Wong
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - A. Wouters
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Yamada
- Permanent Address: Univeristy of Tokyo, Japan
| | - S. Yoshikawa
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K.M Young
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M.C. Zarnstorff
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| |
Collapse
|
10
|
Tiraboschi J, Ray S, Patel K, Teague A, Pace M, Phalora P, Robinson N, Hopkins E, Meyerowitz J, Wang Y, Cason J, Kaye S, Sanderson J, Klenerman P, Fidler S, Frater J, Fox J. The impact of immunoglobulin in acute HIV infection on the HIV reservoir: a randomized controlled trial. HIV Med 2017; 18:777-781. [PMID: 28719012 DOI: 10.1111/hiv.12524] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2017] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Antiretroviral therapy (ART) during acute HIV infection (AHI) restricts the HIV reservoir, but additional interventions are necessary to induce a cure. Intravenous immunoglobulin (IVIG) is not HIV-specific but is safe and temporarily reduces the HIV reservoir in chronic HIV infection. We present a randomized controlled trial to investigate whether IVIG plus ART in AHI reduces the HIV reservoir and immune activation compared with ART alone. METHODS Ten men with AHI (Fiebig II-IV) initiated ART (tenofovir, entricitabine, ritonavir boosted darunavir and raltegravir) at HIV-1 diagnosis and were randomized to ART alone or ART plus 5 days of IVIG, once virally suppressed (week 19). Blood samples were evaluated for viral reservoir, immune activation, immune exhaustion and microbial translocation. Flexible sigmoidoscopy was performed at weeks 19, 24 and 48, and gut proviral DNA and cell numbers determined. RESULTS IVIG was well tolerated and no viral blips (> 50 HIV-1 RNA copies/mL) occurred during IVIG therapy. From baseline to week 48, total HIV DNA in peripheral blood mononuclear cells (PBMCs) (cases: -3.7 log10 copies/106 CD4 cells; controls: -3.87 log10 copies/106 CD4 cells) declined with no differences observed between the groups (P = 0.49). Declines were observed in both groups from week 19 to week 48 in total HIV DNA in PBMCs (P = 0.38), serum low copy RNA (P = 0.57) and gut total HIV DNA (P = 0.55), but again there were no significant differences between arms. Biomarkers of immune activation, immune exhaustion and microbial translocation and the CD4:CD8 ratio were similar between arms for all comparisons. CONCLUSIONS Although safe, IVIG in AHI did not impact total HIV DNA, immune function or microbial translocation in peripheral blood or gut tissue.
Collapse
Affiliation(s)
- J Tiraboschi
- Guys and St Thomas' NHS Foundation Trust, London, UK
| | - S Ray
- Guys and St Thomas' NHS Foundation Trust, London, UK
| | - K Patel
- Guys and St Thomas' NHS Foundation Trust, London, UK
| | - A Teague
- Guys and St Thomas' NHS Foundation Trust, London, UK
| | - M Pace
- University of Oxford, Oxford, UK
| | | | | | | | | | - Y Wang
- Division of Health and Social Care Research, King's College London, London, UK
| | - J Cason
- Department of Infectious Diseases, Kings College London, London, UK
| | - S Kaye
- Oxford National Institute of Health, Oxford, UK
| | - J Sanderson
- Guys and St Thomas' NHS Foundation Trust, London, UK
| | | | - S Fidler
- Imperial College London, London, UK
| | - J Frater
- University of Oxford, Oxford, UK.,Oxford National Institute of Health Research Biomedical Research Centre, Oxford, UK
| | - J Fox
- Guys and St Thomas' NHS Foundation Trust, London, UK
| |
Collapse
|
11
|
Graham C, Kaye S. MANAGED LONG-TERM SERVICES AND SUPPORTS IN CALIFORNIA’S DUALS DEMONSTRATION. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C.L. Graham
- School of Public Health, University of California, Berkeley, Berkeley, California,
- University of California, San Francisco, San Francisco, California
| | - S. Kaye
- University of California, San Francisco, San Francisco, California
| |
Collapse
|
12
|
Maingi R, Canik J, Bell R, Boyle D, Diallo A, Kaita R, Kaye S, LeBlanc B, Sabbagh S, Scotti F, Soukhanovskii V. Effect of progressively increasing lithium conditioning on edge transport and stability in high triangularity NSTX H-modes. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2016.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Fraser-Taliente T, Mackie NE, Kaye S, Nyirenda M, Foster C. Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection. HIV Med 2016; 18:311-313. [PMID: 27981720 DOI: 10.1111/hiv.12467] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - N E Mackie
- Imperial College Healthcare NHS Trust, London, W2 1NY
| | - S Kaye
- Imperial College, London, W2 1NY
| | - M Nyirenda
- Imperial College Healthcare NHS Trust, London, W2 1NY
| | - C Foster
- Imperial College Healthcare NHS Trust, London, W2 1NY
| |
Collapse
|
14
|
Gurrala R, Lang Z, Shepherd L, Davidson D, Harrison E, McClure M, Kaye S, Toumazou C, Cooke GS. Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia. Sci Rep 2016; 6:36000. [PMID: 27829667 PMCID: PMC5103182 DOI: 10.1038/srep36000] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 10/11/2016] [Indexed: 11/10/2022] Open
Abstract
The timely detection of viremia in HIV-infected patients receiving antiviral treatment is key to ensuring effective therapy and preventing the emergence of drug resistance. In high HIV burden settings, the cost and complexity of diagnostics limit their availability. We have developed a novel complementary metal-oxide semiconductor (CMOS) chip based, pH-mediated, point-of-care HIV-1 viral load monitoring assay that simultaneously amplifies and detects HIV-1 RNA. A novel low-buffer HIV-1 pH-LAMP (loop-mediated isothermal amplification) assay was optimised and incorporated into a pH sensitive CMOS chip. Screening of 991 clinical samples (164 on the chip) yielded a sensitivity of 95% (in vitro) and 88.8% (on-chip) at >1000 RNA copies/reaction across a broad spectrum of HIV-1 viral clades. Median time to detection was 20.8 minutes in samples with >1000 copies RNA. The sensitivity, specificity and reproducibility are close to that required to produce a point-of-care device which would be of benefit in resource poor regions, and could be performed on an USB stick or similar low power device.
Collapse
Affiliation(s)
- R Gurrala
- Division of Infectious Diseases, Imperial College, London, England
| | - Z Lang
- DNA Electronics Ltd, Wood Lane, London, England
| | - L Shepherd
- DNA Electronics Ltd, Wood Lane, London, England
| | - D Davidson
- DNA Electronics Ltd, Wood Lane, London, England
| | - E Harrison
- DNA Electronics Ltd, Wood Lane, London, England
| | - M McClure
- Division of Infectious Diseases, Imperial College, London, England
| | - S Kaye
- Division of Infectious Diseases, Imperial College, London, England
| | - C Toumazou
- DNA Electronics Ltd, Wood Lane, London, England.,Department of Bioengineering, Imperial College, London, England
| | - G S Cooke
- Division of Infectious Diseases, Imperial College, London, England
| |
Collapse
|
15
|
McLachlan J, Boussios S, Okines A, Glaessgen D, Bodlar S, Kalaitzaki R, Taylor A, Lalondrelle S, Gore M, Kaye S, Banerjee S. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clin Oncol (R Coll Radiol) 2016; 29:153-160. [PMID: 27838135 DOI: 10.1016/j.clon.2016.10.002] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 10/03/2016] [Accepted: 10/06/2016] [Indexed: 10/20/2022]
Abstract
AIMS Despite recent advances in the primary and secondary prevention of cervical cancer, a significant number of women present with or develop metastatic disease. There is currently no consensus on the standard of care for second-line systemic treatment of recurrent/metastatic cervical cancer. The purpose of this study was to evaluate the second-line systemic therapy used and the associated outcomes in a single cancer centre. MATERIALS AND METHODS A retrospective review of patients with cervical cancer who received one or more lines of treatment for recurrent or metastatic cervical cancer at the Royal Marsden Hospital between 2004 and 2014 was carried out. The primary objective was to establish the types of second-line systemic treatment used. Secondary end points included objective response rate, progression-free survival and overall survival after second-line therapy. RESULTS In total, 75 patients were included in the study; 53 patients (70.7%) received second-line therapy for recurrent/metastatic disease. The most common second-line therapy was weekly paclitaxel (28.3%). Carboplatin-based chemotherapy (24.5%), targeted agent monotherapy within clinical trials (22.6%), docetaxel-based chemotherapy (13.2%), topotecan (9.4%) and gemcitabine (1.9%) were also used. The objective response rate to second-line therapy was 13.2%, which included three partial responses to carboplatin and paclitaxel, two partial responses to docetaxel-based chemotherapy, one partial response to weekly paclitaxel and one partial response to cediranib. Twenty-two patients (41.5%) achieved stable disease at 4 months. The median progression-free survival for women treated with second-line therapy was 3.2 months (95% confidence interval 2.1-4.3) and median overall survival was 9.3 months (95% confidence interval 6.4-12.5). Thirty-nine per cent of patients received third-line therapy. CONCLUSION Seventy per cent of patients treated with first-line systemic therapy for recurrent/metastatic cervical cancer subsequently received second-line treatment but response rates were poor. There remains no standard of care for second-line systemic therapy for advanced cervical cancer. Patients should be considered for clinical trials whenever feasible, including novel targeted agents and immunotherapy.
Collapse
Affiliation(s)
- J McLachlan
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Boussios
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - A Okines
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - D Glaessgen
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Bodlar
- Research Data and Statistics Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - R Kalaitzaki
- Research Data and Statistics Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - A Taylor
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Lalondrelle
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - M Gore
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Kaye
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Banerjee
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
| |
Collapse
|
16
|
McLachlan J, Tunariu N, Lima J, George A, Gore M, Kaye S, Banerjee S. Response to chemotherapy in relapsed low-grade serous ovarian carcinoma: Royal Marsden series of 46 patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Banerjee S, Kilburn L, Bowen R, Tovey H, Hall M, Kaye S, Rustin G, Gore M, McLachlan J, Attygalle A, Tunariu N, Lima J, Chatfield P, Jeffs L, Folkerd E, Hills M, Perry S, Attard G, Dowsett M, Bliss J. Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap T, Banerji U, Lopez J, de Bono J. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Nicolson GP, McGrath ALH, Webster RA, Li J, Kaye S, Malik R, Beijerink NJ. NT-proBNP and cardiac troponin I concentrations in dogs with tick paralysis caused byIxodes holocyclus. Aust Vet J 2016; 94:274-9. [DOI: 10.1111/avj.12468] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 10/12/2015] [Accepted: 11/05/2015] [Indexed: 11/30/2022]
Affiliation(s)
- GP Nicolson
- University Veterinary Teaching Hospital Sydney; Evelyn Williams Building B10, The University of Sydney; New South Wales 2006 Australia
| | - ALH McGrath
- University Veterinary Teaching Hospital Sydney; Evelyn Williams Building B10, The University of Sydney; New South Wales 2006 Australia
| | - RA Webster
- Animal Emergency Service; Carrara QLD Australia
| | - J Li
- Northside Emergency Veterinary Service; NSW; Australia
| | - S Kaye
- Northside Emergency Veterinary Service; NSW; Australia
| | - R Malik
- Centre of Veterinary Education B22; University of Sydney; NSW Australia
| | - NJ Beijerink
- University Veterinary Teaching Hospital Sydney; Evelyn Williams Building B10, The University of Sydney; New South Wales 2006 Australia
| |
Collapse
|
20
|
Matulonis U, Penson R, Domchek S, Kaufman B, Shapira-Frommer R, Audeh M, Kaye S, Molife L, Gelmon K, Robertson J, Mann H, Ho T, Coleman R. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol 2016; 27:1013-1019. [DOI: 10.1093/annonc/mdw133] [Citation(s) in RCA: 123] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 03/03/2016] [Indexed: 11/13/2022] Open
|
21
|
Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P, Pybus OG. Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals. Philos Trans R Soc Lond B Biol Sci 2016; 370:rstb.2014.0241. [PMID: 26194755 PMCID: PMC4528418 DOI: 10.1098/rstb.2014.0241] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Advances in immunoglobulin (Ig) sequencing technology are leading to new perspectives on immune system dynamics. Much research in this nascent field has focused on resolving immune responses to viral infection. However, the dynamics of B-cell diversity in early HIV infection, and in response to anti-retroviral therapy, are still poorly understood. Here, we investigate these dynamics through bulk Ig sequencing of samples collected over 2 years from a group of eight HIV-1 infected patients, five of whom received anti-retroviral therapy during the first half of the study period. We applied previously published methods for visualizing and quantifying B-cell sequence diversity, including the Gini index, and compared their efficacy to alternative measures. While we found significantly greater clonal structure in HIV-infected patients versus healthy controls, within HIV patients, we observed no significant relationships between statistics of B-cell clonal expansion and clinical variables such as viral load and CD4+ count. Although there are many potential explanations for this, we suggest that important factors include poor sampling resolution and complex B-cell dynamics that are difficult to summarize using simple summary statistics. Importantly, we find a significant association between observed Gini indices and sequencing read depth, and we conclude that more robust analytical methods and a closer integration of experimental and theoretical work is needed to further our understanding of B-cell repertoire diversity during viral infection.
Collapse
Affiliation(s)
| | - Astrid Gall
- Wellcome Trust Sanger Institute, Cambridge, UK
| | - Rachael Bashford-Rogers
- Wellcome Trust Sanger Institute, Cambridge, UK Cambridge Institute of Medical Research, University of Cambridge, Cambridge, UK
| | - S J Fidler
- Faculty of Medicine, Imperial College, London, UK
| | - S Kaye
- Faculty of Medicine, Imperial College, London, UK
| | - J N Weber
- Faculty of Medicine, Imperial College, London, UK
| | - M O McClure
- Faculty of Medicine, Imperial College, London, UK
| | | | - Paul Kellam
- Wellcome Trust Sanger Institute, Cambridge, UK MRC/UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, UK
| | | |
Collapse
|
22
|
Banerjee S, Ledermann J, Matulonis U, Molife L, Friedlander M, Fielding A, Robertson J, Spencer S, McMurtry E, Kaye S. 2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31525-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Seifert H, Georgiou A, Alexander H, Bodla S, Kaye S, Nobbenhuis M, Gore M, Banerjee S. 2763 Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31529-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Foster C, Kaye S, Smith C, Mackie NE. HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study. J Virus Erad 2015; 1:173-8. [PMID: 27482409 PMCID: PMC4946736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
OBJECTIVES Retrospective analysis of evolution of HIV tropism and association with disease progression in perinatal HIV-1 infection (PaHIV). METHODOLOGY Eligible patients with PaHIV were grouped as slow, rapid or long-term non-progressors (LTNP). The V3 region of gp120 was sequenced from stored plasma samples and tropism determined by geno2pheno algorithm (FPR 5.75%). Logistic regression with generalised estimating equations assessed factors associated with R5 virus. Time to tropism change was assessed using standard survival methods. RESULTS At baseline (n=48) median age was 12 years (IQR 9.3-14.8), 52% were female, 79% were Black African, 96% were non-B subtypes and 81% (39/48) had R5-using virus. Median follow-up was 7.7 years (308.6 person-years), with a median of five (range 1-14) samples per subject (total 252). Analysing all samples, R5 virus was associated with higher current CD4 cell count (median 520 cells/mm(3) R5 vs 202 for X4, P=0.0005), LTNP (35% vs 11%, P=0.05), non-Black ethnicity (74% vs 89%, P=0.05) and female gender (55% vs 28%, P=0.005). Twelve of 38 (31%) with R5 virus at baseline switched to X4/dual-using virus, with an estimated 5-year risk of switch of 24.4% (95% CI 9.7-39.2%) predicted by lower current CD4 cell count (unadjusted HR 0.62/50 cells higher, 95% CI 0.47-0.81, P=0.0006). Eleven of 19 (58%) with X4/dual-using virus subsequently had R5 virus at one or more time points. CONCLUSION Maraviroc was a treatment option for 81% at 12 years, falling to 56% at 18 years, with lower CD4 cell count predictive of co-receptor switching. Paediatric studies of CCR5 antagonists should be expedited to ensure they are an early treatment option before tropism switching occurs.
Collapse
Affiliation(s)
- C Foster
- Department of GU Medicine,
Imperial College Healthcare NHS Trust,
London,
UK,Corresponding author: Caroline Foster,
Department of GU MedicineImperial College Healthcare NHS Trust,
Praed StreetLondonW2 1NY,
UK
| | - S Kaye
- Department of Retrovirology,
Imperial College London,
UK
| | - C Smith
- Research Department of Infection and Population Health,
University College London,
UK
| | - NE Mackie
- Department of GU Medicine,
Imperial College Healthcare NHS Trust,
London,
UK
| |
Collapse
|
25
|
Foster C, Kaye S, Smith C, Mackie N. HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study. J Virus Erad 2015. [DOI: 10.1016/s2055-6640(20)30505-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Abstract
OBJECTIVE The objective of this study is to review clinical outcomes of recommendations made by a multidisciplinary paediatric virtual clinic (PVC) for complex case management of paediatric HIV as a model of care within a tertiary network. DESIGN A retrospective review of the clinical outcomes of paediatric and adolescent (0-21 years) referrals to the PVC at St. Mary's Hospital, Imperial College Healthcare NHS Trust, London was performed between October 2009 and November 2013. RESULTS 234 referrals were made for 182 children from 37 centres, discussed in 42 meetings (median age 13 years, IQR 10-15 years). Reasons for referral included virological failure (44%), simplification of the current regimen (24%) and antiretroviral drug complications (24%). At latest follow-up, PVC advice had been instituted in 80% of referrals. Suppression following virological failure was achieved in 48% following first referral and 57% following subsequent discussions and was maintained in 95% of children referred for regimen simplification. Following advice, dyslipidaemia resolved in 42% and liver function normalised in 73% with biochemical hepatitis. Adherence support aided resolution of viraemia in nine children and 12% of referrals resulted in additional support, including psychology, social services and mental health input. CONCLUSIONS Combined multidisciplinary virtual input with adult expertise in resistance and newer agents, paediatric knowledge of pill swallowing, childhood formulations/weight banding and parental support, assists complex treatment decision making in paediatric HIV infection. The Virtual Clinic model could be applied to the management of other rare complex diseases of childhood within a clinical network.
Collapse
Affiliation(s)
- Kirsty Le Doare
- St. Mary's Hospital, Imperial College NHS Trust, London, UK,Department of Paediatrics, Imperial College London, London, UK
| | - N E Mackie
- St. Mary's Hospital, Imperial College NHS Trust, London, UK
| | - S Kaye
- St. Mary's Hospital, Imperial College NHS Trust, London, UK
| | - A Bamford
- St. Mary's Hospital, Imperial College NHS Trust, London, UK,Great Ormond Street Hospital, London, UK
| | - S Walters
- St. Mary's Hospital, Imperial College NHS Trust, London, UK,Department of Paediatrics, Imperial College London, London, UK
| | - C Foster
- St. Mary's Hospital, Imperial College NHS Trust, London, UK
| |
Collapse
|
27
|
Affiliation(s)
- S. Yadav
- Royal Liverpool University Hospital; Liverpool UK
| | - S. Kaye
- Royal Liverpool University Hospital; Liverpool UK
| | - N. Wilson
- Royal Liverpool University Hospital; Liverpool UK
| |
Collapse
|
28
|
Glasspool RM, Brown R, Gore ME, Rustin GJS, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, Gabra H, Halford SER, Walker J, Appleton K, Ullah R, Kaye S. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 2014; 110:1923-9. [PMID: 24642620 PMCID: PMC3992493 DOI: 10.1038/bjc.2014.116] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 02/05/2014] [Accepted: 02/09/2014] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-2'-deoxycytodine (decitabine) can reverse resistance to carboplatin in women with relapsed ovarian cancer. METHODS Patients progressing 6-12 months after previous platinum therapy were randomised to decitabine on day 1 and carboplatin (AUC 6) on day 8, every 28 days or carboplatin alone. The primary objective was response rate in patients with methylated hMLH1 tumour DNA in plasma. RESULTS After a pre-defined interim analysis, the study closed due to lack of efficacy and poor treatment deliverability in 15 patients treated with the combination. Responses by GCIG criteria were 9 out of 14 vs 3 out of 15 and by RECIST were 6 out of 13 vs 1 out of 12 for carboplatin and carboplatin/decitabine, respectively. Grade 3/4 neutropenia was more common with the combination (60% vs 15.4%) as was G2/3 carboplatin hypersensitivity (47% vs 21%). CONCLUSIONS With this schedule, the addition of decitabine appears to reduce rather than increase the efficacy of carboplatin in partially platinum-sensitive ovarian cancer and is difficult to deliver. Patient-selection strategies, different schedules and other demethylating agents should be considered in future combination studies.
Collapse
Affiliation(s)
- R M Glasspool
- The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
| | - R Brown
- Department Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
| | - M E Gore
- Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
| | - G J S Rustin
- Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK
| | - I A McNeish
- St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK
| | - R H Wilson
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AB, N. Ireland, UK
| | - S Pledge
- Sheffield Weston Park Hospital, Whitham Road, Sheffield, South Yorkshire S10 2SJ, UK
| | - J Paul
- The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
| | - M Mackean
- Edinburgh Western General Hospital, Crewe Road S, Edinburgh EH4 2XU, UK
| | - G D Hall
- St James's Institute of Oncology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK
| | - H Gabra
- Department Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
| | - S E R Halford
- Drug Development Office Cancer Research UK, Angel Building, 407 Street, John Street, Islington, London EC1V 4AD, UK
| | - J Walker
- Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK
| | - K Appleton
- Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK
| | - R Ullah
- Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK
| | - S Kaye
- Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
| |
Collapse
|
29
|
Kaye S, White M, Lewis I. Processing biases towards gain-framed messages may lead reward sensitive individuals to adopt safer driving behaviours. Personality and Individual Differences 2014. [DOI: 10.1016/j.paid.2013.07.359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken J, Ghamande S, Harnett P, Del Prete S, Green J, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann Oncol 2014; 25:160-5. [DOI: 10.1093/annonc/mdt515] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
31
|
Sordo L, Indave BI, Degenhardt L, Barrio G, Kaye S, Ruíz-Pérez I, Bravo MJ. A systematic review of evidence on the association between cocaine use and seizures. Drug Alcohol Depend 2013; 133:795-804. [PMID: 24051062 DOI: 10.1016/j.drugalcdep.2013.08.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 07/25/2013] [Accepted: 08/22/2013] [Indexed: 11/17/2022]
Abstract
BACKGROUND Institutional monographs/medical textbooks mention seizures as a neurological complication of cocaine, but no systematic reviews (SRs) have been published on this issue. We aimed to conduct a SR of the literature on the relationship between cocaine use and seizures and to summarize the biological plausibility of that relationship. METHODS The pathophysiological mechanisms that may underlie an association between cocaine and seizures were summarized; a SR was then performed using three databases (EMBASE, Medline, PsycINFO) and the Cochrane-library to search for published papers (1980-2012) aimed at quantifying the associations between cocaine use and seizures. The inclusion criteria for selection were: articles based on clinical trials, cohort, case-control (CC) or cross-sectional (CS) studies, participants ≥ 14 years old and not pregnant, and use of cocaine in the last 72 h. Information was extracted, evaluated and cross-checked independently by two researchers. RESULTS Of the 1243 potentially relevant articles initially identified; one CC and 22 CS studies were finally selected. The CC study did not find cocaine use to be a risk-factor for seizures. In addition to the limitations of the CS design, these studies had important methodological weaknesses and biases. CONCLUSIONS Despite its biological plausibility, no rigorous scientific evidence supports a causal relationship between cocaine use and seizures. The misinterpretation of the role of cocaine may have important implications in medical services. Well-conducted studies are urgently needed.
Collapse
Affiliation(s)
- L Sordo
- National Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain; Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University, Madrid, Spain; Network Biomedical Research Centers, Epidemiology and Public Health (CIBERESP in Spanish), Spain.
| | | | | | | | | | | | | |
Collapse
|
32
|
van der Sande MAB, Luong TN, Schim van der Loeff MF, Sabally S, Aveika AA, Corrah T, Sarge-Njie R, Kaye S, Whittle HC. Dual HIV-1 and HIV-2 infection in a West African infant. ACTA ACUST UNITED AC 2013; 24:277-8. [PMID: 15479581 DOI: 10.1179/027249304225019073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
33
|
Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24:1416-8. [PMID: 23524863 DOI: 10.1093/annonc/mdt074] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013; 108:250-8. [PMID: 23385789 PMCID: PMC3566823 DOI: 10.1038/bjc.2012.541] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Revised: 10/10/2012] [Accepted: 11/02/2012] [Indexed: 12/21/2022] Open
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.
Collapse
Affiliation(s)
- M Hall
- Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Kagimu M, Guwatudde D, Rwabukwali C, Kaye S, Walakira Y, Ainomugisha D. Religiosity for HIV prevention in Uganda: a case study among Muslim youth in Wakiso district. Afr Health Sci 2013. [DOI: 10.4314/ahs.v12i3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
36
|
Sandhu S, Wilding G, Schelman W, Omlin A, Kreischer N, Carpenter C, Iannone R, Kaye S, de-Bono J, Wenham R. 352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72150-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Miller R, Brough R, Bajrami I, Kaye S, Banerjee S, Lord C, Ashworth A. 105 Functional Profiling of Clear Cell Ovarian Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71903-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Ono M, Bell M, Kaita R, Kugel H, Ahn JW, Allain J, Battaglia D, Bell R, Canik J, Ding S, Gerhardt S, Gray T, Guttenfelder W, Hosea J, Jaworski M, Kallman J, Kaye S, LeBlanc B, Maingi R, Mansfield D, McLean A, Menard J, Muller D, Nelson B, Nygren R, Paul S, Raman R, Ren Y, Ryan P, Sabbagh S, Scotti F, Skinner C, Soukhanovskii V, Surla V, Taylor C, Timberlake J, Yuh H, Zakharov L. Recent progress of NSTX lithium program and opportunities for magnetic fusion research. Fusion Engineering and Design 2012. [DOI: 10.1016/j.fusengdes.2011.10.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
39
|
Kugel H, Allain J, Bell M, Bell R, Diallo A, Ellis R, Gerhardt S, Heim B, Jaworski M, Kaita R, Kallman J, Kaye S, LeBlanc B, Maingi R, McLean A, Menard J, Mueller D, Nygren R, Ono M, Paul S, Raman R, Roquemore A, Sabbagh S, Schneider H, Skinner C, Soukhanovskii V, Taylor C, Timberlake J, Viola M, Zakharov L. NSTX plasma operation with a Liquid Lithium Divertor. Fusion Engineering and Design 2012. [DOI: 10.1016/j.fusengdes.2011.07.010] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Kagimu M, Guwatudde D, Rwabukwali C, Kaye S, Walakira Y, Ainomugisha D. Religiosity for HIV prevention in Uganda: a case study among Muslim youth in Wakiso district. Afr Health Sci 2012; 12:282-290. [PMID: 23382741 PMCID: PMC3557679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
BACKGROUND Evidence for the association between religiosity and HIV infections is limited. Sujda, the hyper-pigmented spot on the forehead due to repeated prostration during prayers and fasting to worship, involving abstaining from food, drink and sex during daytime in Ramadhan and other specified days, are measures of religiosity among Muslims OBJECTIVES To assess the association between religiosity and HIV infections. METHODS This was an unmatched case-control study with 29 HIV positive cases and 116 HIV negative controls, from 1224 Muslims, 15-24 years. RESULTS Respondents without Sujda had more HIV infections (odds ratio 2.90, 95% CI 1.07-7.86, p=0.029). Those with Sujda were more likely to abstain from sex (odds ratio 1.69, 95% CI 1.31-2.20, p<0.001) and be faithful in marriage (odds ratio 1.69, 95% CI 1.11-2.57, p=0.012). Respondents without Sujda were more likely to have ever taken alcohol before sex (odds ratio 5.00, 95% CI 1.39-17.95, p=0.006) and to have ever used narcotics (odds ratio 2.12, 95% CI, 1.11-4.05, p=0.019). Respondents who fasted less, had more HIV infections (odds ratio 2.46, 95% CI 1.07-5.67, p=0.028). CONCLUSION Sujda and fasting were associated with lower HIV infections. Imams should use this information to intensify the Islamic approach to HIV prevention.
Collapse
Affiliation(s)
- M Kagimu
- Islamic Medical Association of Uganda, Uganda.
| | | | | | | | | | | |
Collapse
|
41
|
Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012; 107:1093-9. [PMID: 22935583 PMCID: PMC3461162 DOI: 10.1038/bjc.2012.368] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Background: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. Methods: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-label, dose-escalation study of AZD8055 starting at 10 mg twice-daily oral dosing (BID). Results: Forty-nine patients received AZD8055. Dose-limiting toxicities were reported at 40 mg (n=1), 90 mg (n=1) and 120 mg (n=3) BID; all were grade 3 rises in transaminases, reversible in all patients, apart from one who had liver metastases. The maximum tolerated dose was defined as 90 mg BID. The most frequent adverse events assessed to be related to AZD8055 were increased alanine aminotransferase (22%), increased aspartate aminotransferase (22%) and fatigue (16%). AZD8055 was rapidly absorbed (median tmax ∼0.5 h) and exposure increased with increasing doses. Seven patients had stable disease for ⩾4 months. Partial metabolic responses, assessed by fluorodeoxyglucose positron emission tomography, were observed at ⩾40 mg BID (n=8 at day 35). Conclusion: The maximum tolerated dose for AZD8055 is 90 mg BID. Apart from elevated transaminases, which occurred at most dose levels, the drug had an acceptable toxicity profile; however, no RECIST responses were seen.
Collapse
Affiliation(s)
- A Naing
- The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kagimu M, Kaye S, Ainomugisha D, Lutalo I, Walakira Y, Guwatudde D, Rwabukwali C. Evidence-based monitoring and evaluation of the faith-based approach to HIV prevention among Christian and Muslim youth in Wakiso district in Uganda. Afr Health Sci 2012; 12:119-28. [PMID: 23056016 DOI: 10.4314/ahs.v12i2.7] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The Islamic Medical Association of Uganda, has been implementing the faith-based approach to HIV prevention without baseline data on expected positive outcomes. OBJECTIVES To establish evidence-based baseline data on expected positive outcomes of the faith-based approach to HIV prevention. METHODS A cross-sectional study of 15-24 year-old youths was analyzed for significant associations between HIV infections, risky behaviors, and religiosity RESULTS HIV prevalence was 3.6% among Christians and 2.4% among Muslims. Abstaining from sex among teenagers was at 54% for Christians and 58% for Muslims. Being faithful in marriage among males was at 41% for Christians and 34% for Muslims and among females it was 65% for Christians and 69% for Muslims. Praying privately was associated with lower HIV infections and was observed among 60% of Christians. Sujda, the hyperpigmented marker of regular prayers on the forehead of Muslims was associated with lower HIV infections and observed in 42% of them. Ever drank alcohol was associated with higher HIV prevalence and observed in 52% of Christians and 17% of Muslims. Male circumcision rates were 15% for Christians and 98% for Muslims. CONCLUSION A sero-behavioral-religiosity survey can provide evidence-based data for monitoring and evaluation of the faith-based approach to HIV prevention.
Collapse
Affiliation(s)
- M Kagimu
- Islamic Medical Association of Uganda, Uganda.
| | | | | | | | | | | | | |
Collapse
|
43
|
Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EGE, Barriuso J, Sandhu S, Tan DSW, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer 2012; 106:1728-34. [PMID: 22531637 PMCID: PMC3364128 DOI: 10.1038/bjc.2012.158] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel. Methods: Patients with advanced solid tumours received saracatinib once-daily oral tablets in combination with either carboplatin AUC 5 every 3 weeks (q3w), paclitaxel 175 mg m−2 q3w, paclitaxel 80 mg m−2 every 1 week (q1w), or carboplatin AUC 5 plus paclitaxel 175 mg m−2 q3w. The primary endpoint was safety/tolerability. Results: A total of 116 patients received saracatinib 125 (N=20), 175 (N=44), 225 (N=40), 250 (N=9), or 300 mg (N=3). There were no clear dose-related trends within each chemotherapy regimen group in number or severity of adverse events (AEs). However, combining all groups, the occurrence of grade ⩾3 asthenic AEs (all causality) was dose-related (125 mg, 10% 175 mg, 20% ⩾225 mg, 33%), and grade ⩾3 neutropenia occurred more commonly at doses ⩾225 mg. There was no evidence that saracatinib affected exposure to carboplatin or paclitaxel, or vice versa. Objective responses were seen in 5 out of 44 patients (11%) receiving carboplatin plus paclitaxel q3w, and 5 out of 24 (21%) receiving paclitaxel q1w. Conclusion: Saracatinib doses up to 175 mg with paclitaxel with/without carboplatin showed acceptable toxicity in most patients, and are suitable for further trials.
Collapse
Affiliation(s)
- S Kaye
- Drug Development Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kagimu M, Guwatudde D, Rwabukwali C, Kaye S, Walakira Y, Ainomugisha D. Religiosity for HIV prevention in Uganda: a case study among Christian youth in Wakiso district. Afr Health Sci 2012; 12:17-25. [PMID: 23066415 PMCID: PMC3462513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
BACKGROUND Utilization of religious institutions is one of the strategies for HIV prevention in Uganda. There is limited data on the association between religiosity and HIV infection rates. OBJECTIVE To determine the association between religiosity and HIV prevalence rates among Christians. METHODS An unmatched case-control study was done. Data from 106 HIV positive cases and 424 HIV negative controls between 15- 24 years were analyzed. RESULTS Lower religiosity was associated with higher HIV infection rates when the following dimensions were analyzed: feeling guided by God in daily activities (odds ratio 1.90, 95%CI 1.03-3.50, p=0.035), feeling thankful for God's blessings (odds ratio 1.76, 95%CI 1.01-3.11, p=0.042), praying privately (odds ratio 2.02, 95%CI 1.30-3.11, p=0.001), trying hard to be patient in life (odds ratio1.74, 95%CI 1.07-2.84, p=0.024) and trying hard to love God (odds ratio 1.57, 95%CI 1.01-2.42, p=0.039). Higher HIV infection rates were associated with having multiple life-time sexual partners (odds ratio 5.37, 95%CI 1.86-15.47, p<0.001), ever drinking alcohol (odds ratio 2.28, 95%CI 1.43-3.65, p<0.001) and ever using narcotics for recreation (odds ratio 2.49, 95%CI 1.14-5.44, p=0.018). CONCLUSION Lower levels of several dimensions religiosity are significantly associated with higher HIV infection rates. This data supports strengthening religiosity in HIV prevention strategies.
Collapse
Affiliation(s)
- M Kagimu
- Islamic Medical Association of Uganda, Kampala, Uganda.
| | | | | | | | | | | |
Collapse
|
45
|
Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother 2011; 67:206-12. [DOI: 10.1093/jac/dkr427] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Velasco AP, Monk B, Kaye S, Vermorken J, Nieto A, Gomez J, Park Y, Parekh T, Colombo N, Vergote I. 8031 POSTER Prediction of Overall Survival (OS) Adjusted by Continuous Platinum-free Interval (PFI) at Fixed Timepoints in Patients With Recurrent Ovarian Cancer (ROC) – Results From OVA-301. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72119-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, Poole C, Lind M, Persic M, Essapen S, Gore M, Calvert H, Stredder C, Wagner A, Giurescu M, Kaye S. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22:2411-2416. [PMID: 21372124 DOI: 10.1093/annonc/mdq780] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer. PATIENTS AND METHODS Women with ovarian cancer recurring within 6 months of end of last platinum-containing treatment received sagopilone 16 mg/m(2) as a 3- or 0.5-h i.v. infusion every 21 days for up to 6 weeks. RESULTS Sixty-three patients received sagopilone as a 3-h (n=38) or 0.5-h (n=25) infusion. There were nine confirmed tumour responses [by modified RECIST (n=8) and by Gynecologic Cancer Intergroup CA-125 criteria (n=1)] in 57 patients assessable for efficacy overall [three (13%) with 0.5-h and six (18%) with 3-h infusions]. The 0.5-h arm was closed when it failed to meet its target efficacy. Main drug-related adverse events were peripheral sensory neuropathy (73%; 16% grade 3), nausea (37%; 2% grade 3), fatigue (35%; 3% grade 3) and arthralgia (30%; 5% grade 3). Overall incidence of peripheral sensory neuropathy was similar in both treatment arms, with no grade 4 neuropathy events. No acute allergic infusion reactions were observed. CONCLUSION Sagopilone is effective, with balanced tolerability, in patients with recurrent platinum-resistant ovarian cancer.
Collapse
Affiliation(s)
- G Rustin
- Medical Oncology, Mount Vernon Cancer Centre, Northwood.
| | - N Reed
- Department of Clinical Oncology, Beatson Oncology Centre, Gartnavel General Hospital, Glasgow
| | - G C Jayson
- School of Cancer and Enabling Sciences, University of Manchester and Christie Hospital, Manchester
| | - J A Ledermann
- Department of Oncology, UCL Hospitals and UCL Cancer Institute, London
| | - M Adams
- Clinical Oncology, Velindre NHS Trust, Cardiff
| | - T Perren
- Department of Medical Oncology, St James's Institute of Oncology, St James's University Hospital, Leeds
| | - C Poole
- Arden Cancer Research Centre, University Hospitals Coventry and Warwickshire, Coventry
| | - M Lind
- Department of Oncology, Princess Royal Hospital, Hull
| | - M Persic
- Clinical Oncology, Derbyshire Royal Infirmary, Derby
| | - S Essapen
- Clinical Oncology, The Royal Surrey County Hospital, Guildford
| | - M Gore
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London
| | | | | | - A Wagner
- Global Medical Development Oncology, Bayer Schering Pharma AG, Berlin, Germany
| | - M Giurescu
- Global Medical Development Oncology, Bayer Schering Pharma AG, Berlin, Germany
| | - S Kaye
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London
| |
Collapse
|
48
|
Majeski R, Kugel H, Kaita R, Avasarala S, Bell M, Bell R, Berzak L, Beiersdorfer P, Gerhardt S, Granstedt E, Gray T, Jacobson C, Kallman J, Kaye S, Kozub T, LeBlanc B, Lepson J, Lundberg D, Maingi R, Mansfield D, Paul S, Pereverzev G, Schneider H, Soukhanovskii V, Strickler T, Stotler D, Timberlake J, Zakharov L. The impact of lithium wall coatings on NSTX discharges and the engineering of the Lithium Tokamak eXperiment (LTX). Fusion Engineering and Design 2010. [DOI: 10.1016/j.fusengdes.2010.03.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2010; 17:115-22. [PMID: 19874478 PMCID: PMC2817443 DOI: 10.1111/j.1365-2893.2009.01168.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The main objectives of this study were to define the occurrence and levels of hepatitis B virus (HBV) DNA in asymptomatic HBV carriers, cirrhosis patients and hepatocellular carcinoma (HCC) cases from The Gambia, and to evaluate the risk for cirrhosis or HCC associated with HBV viremia. We used sensitive real-time quantitative PCR assays to measure HBV DNA in samples from a case-control study consisting of 60 asymptomatic HBV carriers, 53 cirrhotic patients and 129 HCC cases. Logistic regression was used to estimate the risks of cirrhosis and HCC associated with HBV-DNA levels and HBV e antigenemia (HBeAg) detection (a surrogate marker for viral replication). Detectable HBV viremia and HBeAg positivity were both significantly associated with cirrhosis (increasing risk by fourfold and 11-fold respectively) and with HCC (increasing risk by sixfold and threefold respectively). HBV-DNA levels were significantly higher in both HCC cases and cirrhotic patients compared to asymptomatic carriers (P < 0.01 for both). High-level HBV DNA (>10,000 copies/mL) was strongly associated with both HCC and cirrhosis (17- and 39-fold increased risk). Lower level HBV viremia (200-10,000 copies/mL) conferred a significant risk of HCC, although the association with cirrhosis was not significant. In conclusion, we find that high HBV-DNA levels are strongly associated with the serious sequelae of HBV infection, independent of HBeAg status. While risk for cirrhosis and for HCC notably increases at HBV-DNA levels >or=10,000 copies/mL, low-level viremia was also associated with significant risk for HCC.
Collapse
Affiliation(s)
- M E Mendy
- Viral Diseases Programe, Medical Research CouncilBanjul, The Gambia
| | - T Welzel
- Division of Cancer Epidemiology and Genetics, National Cancer InstituteRockville, MD, USA
| | - O A Lesi
- Lagos University Teaching HospitalLagos, Nigeria
| | - P Hainaut
- International Agency for Research on CancerLyon, France
| | - A J Hall
- London School of Hygiene and Tropical MedicineLondon; England
| | - M H Kuniholm
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public HealthBaltimore, MD, USA
| | - S McConkey
- Royal College of Surgeons in IrelandDublin, Ireland
| | - J J Goedert
- Division of Cancer Epidemiology and Genetics, National Cancer InstituteRockville, MD, USA
| | - S Kaye
- Imperial CollegeLondon, UK
| | - S Rowland-Jones
- Viral Diseases Programe, Medical Research CouncilBanjul, The Gambia
| | - H Whittle
- Viral Diseases Programe, Medical Research CouncilBanjul, The Gambia
| | - G D Kirk
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public HealthBaltimore, MD, USA
| |
Collapse
|
50
|
Poveda A, Kaye S, Herzog T, Ghatage P, Meerpohl H, Ngan H, Emerich J, Tercero J, Ricci D, Monk B. 8005 Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) + PLD in the ET743-OVA-301 clinical trial. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71527-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|